Automated Telephone Outreach With Speech Recognition to Improve Diabetes Care: A Randomized Controlled Study

Diabetes Mellitus Clinical Trial

— ATO-SR-DM  

Official title:

Automated Telephone Outreach With Speech Recognition to Improve Diabetes Care: A Randomized Controlled Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00790530
• Other study ID #: 1-05-JF-40
• Status: Completed
• Phase: N/A
• First received: November 11, 2008
• Last updated: November 11, 2008
• Start date: June 2006
• Est. completion date: October 2007

Study information

• Verified date: November 2008
• Source: Harvard Pilgrim Health Care
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effectiveness of automated telephone outreach with speech recognition to improve diabetes care.

Description:

Randomly allocate a total of 1200 health plan members with diabetes to automated telephone outreach with speech recognition (ATO-SR; N = 600) or usual care (N = 600). The intervention is a series of three calls, using automated calls, originating from the health plan, using interactive speech recognition technology, spaced approximately 4-6 weeks apart, to encourage participants to fulfill the recommended testing (dilated eye examinations, glycated hemoglobin, LDL-cholesterol, microalbumin) that had not been performed received in the preceding year.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1200
• Est. completion date: October 2007
• Est. primary completion date: October 2007
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age 18 years or older

• Diabetes, defined as either 1) filled a prescription for insulin or an oral hypoglycemic agent; or, 2) had two outpatient or one inpatient or two outpatients encounter claims with an ICD9-CM or CPT code indicating diabetes.

• Gap in a key diabetes management metric as evidenced by no claim for a dilated eye examination in the prior 15 months and no claim for one or more of the following tests: glycated hemoglobin, LDL-cholesterol, or microalbumin. (Individuals with evidence of having received ACE-inhibitors or angiotensin receptor blockers were considered to have had a microalbumin test.)

Exclusion Criteria:

• No primary care clinician in the data base

• Those who had previously asked the health plan to exclude them from research or quality improvement

• Women whose claim records contained diagnoses suggesting gestational diabetes

Related Conditions & MeSH terms

• Diabetes Mellitus

Intervention

Behavioral:
• Automated Telephone Outreach with Speech Recognition
Automated Telephone Outreach with Speech Recognition

Other:
• Usual Care
Usual Care

Locations

Country	Name	City	State
United States	Harvard Pilgrim Health Care	Boston	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Harvard Pilgrim Health Care	American Diabetes Association

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Completion of dilated eye examination		12-months following intervention
Secondary	Completion of glycated hemoglobin testing (HbA1c)		one-year following intervention
Secondary	Completion of LDL-cholesterol testing		one year following intervention
Secondary	Completion of microalbumin testing		one-year following intervention